0001860782-22-000029.txt : 20220613 0001860782-22-000029.hdr.sgml : 20220613 20220613160922 ACCESSION NUMBER: 0001860782-22-000029 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220608 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220613 DATE AS OF CHANGE: 20220613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 2seventy bio, Inc. CENTRAL INDEX KEY: 0001860782 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 863658454 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40791 FILM NUMBER: 221011688 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02210 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02210 8-K 1 tsvt-8xkannualmeetingresul.htm 8-K Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 8, 2022
2seventy bio, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________________________
Delaware
001-40791
86-3658454
(State or other jurisdiction
of incorporation)		(Commission File Number)(IRS Employer
Identification No.)
60 Binney Street,
Cambridge, MA
02142
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (339) 499-9300
Not Applicable
(Former name or former address, if changed since last report)
_____________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per shareTSVTThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.07     Submission of Matters to a Vote of Security Holders.

On June 8, 2022, 2seventy bio, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following proposals: (i) the election of each of Nick Leschly and Ramy Ibrahim, M.D. as Class I members of the Board of Directors to serve until the Company’s 2025 annual meeting of stockholders (“Proposal 1”), and (ii) the ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 (“Proposal 2”). As of April 11, 2022, the record date for the Annual Meeting, 37,615,797 shares of the Company’s common stock were issued and outstanding. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below:
1. The Company’s stockholders re-elected the two persons listed below as Class I directors, pursuant to Proposal 1. The voting results were as follows:
  Votes For Votes
Withheld		  Broker
Non-Votes
Nick Leschly
 18,883,8602,934,3442,761,239
Ramy Ibrahim, M.D.
 20,893,360924,8442,761,239

2. The Company’s stockholders approved Proposal 2. The voting results were as follows:
 
Votes For Votes Against Abstentions 
24,531,86129,58817,994






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
2seventy bio, Inc.
Dated: June 13, 2022By:/s/ Nick Leschly
Name: Nick Leschly
Title: Chief Executive Officer